Sutro Biopharma (STRO) Long-Term Debt Repayments (2019 - 2024)

Sutro Biopharma's Long-Term Debt Repayments history runs 5 years deep, the most recent figure standing at $4.1 million for Q1 2024.

• In Q1 2024, Long-Term Debt Repayments rose 30.66% year-over-year to $4.1 million; the TTM figure through Dec 2024 stood at $4.1 million (down 67.34% YoY), while the FY2024 annual figure was $4.1 million, down 67.34% from the prior year.
• Long-Term Debt Repayments came in at $4.1 million for Q1 2024 at Sutro Biopharma, up from $3.1 million in the prior quarter.
• In the past five years, Long-Term Debt Repayments ranged from a high of $10.0 million in Q1 2020 to a low of $3.1 million in Q3 2022.
• A 4-year average of $4.1 million and a median of $3.1 million in 2022 frame the typical range for Long-Term Debt Repayments.
• Across the five-year window, Long-Term Debt Repayments surged 1900.0% in 2020 and changed 0.0% in 2023, its largest moves.
• Sutro Biopharma's Long-Term Debt Repayments stood at $10.0 million in 2020, then slumped by 68.75% to $3.1 million in 2022, then changed by 0.0% to $3.1 million in 2023, then jumped by 30.66% to $4.1 million in 2024.
• According to Business Quant data, Long-Term Debt Repayments over the past three periods registered $4.1 million, $3.1 million, and $3.1 million for Q1 2024, Q4 2023, and Q3 2023 respectively.

Peer Comparison